Watch RLMD. Know when insiders buy.
One email the day a filing lands. Free.
RLMD
RELMADA THERAPEUTICS, INC.
4.07
−0.02 −0.49%
USD · close Sep 10
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
74
PASS · insiders 85, shorts 63
Insiders, 90 days
+$1.7M
net buying · 4 buys, 0 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $434.1MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$61.9MNET CASH —52W 1.51 – 7.86SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$15M | −$12.9M | — | -0.11 | −$9.6M | — | — | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$19.5M | −$19.1M | — | -0.22 | −$15.1M | — | — | Aug 6 |
| Q4 2025 · Dec 31derived | — | — | — | −$20.3M | −$19.9M | — | -0.29 | −$14.6M | — | — | Mar 19 |
| Q3 2025 · Sep 30 | — | — | — | −$10.3M | −$10.1M | — | -0.30 | −$6.7M | — | — | Nov 13 |
| Q2 2025 · Jun 30 | — | — | — | −$10.2M | −$9.9M | — | -0.30 | −$6.4M | — | — | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | −$18.2M | −$17.6M | — | -0.58 | −$18.1M | — | — | Aug 6 |
| Q4 2024 · Dec 31derived | — | — | — | −$19.1M | −$18.7M | — | -0.62 | −$8.8M | — | — | Mar 19 |
| Q3 2024 · Sep 30 | — | — | — | −$23M | −$21.7M | — | -0.72 | −$16.7M | — | — | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$18.8M | −$17.8M | — | -0.59 | −$13.3M | — | — | Nov 13 |
| Q1 2024 · Mar 31 | — | — | — | −$23M | −$21.8M | — | -0.72 | −$13M | — | — | Nov 13 |
| Q4 2023 · Dec 31derived | — | — | — | −$26.8M | −$25.2M | — | -0.83 | −$10.2M | — | — | Mar 27 |
| Q3 2023 · Sep 30 | — | — | — | −$22.7M | −$22M | — | -0.73 | −$11.6M | — | — | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$59.1M | −$57.4M | — | -1.45 | −$45.8M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$83.9M | −$80M | — | -2.65 | −$51.8M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$103.7M | −$98.8M | — | -3.28 | −$51.7M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$161.2M | −$157M | — | -5.30 | −$103.8M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$125.7M | −$125.8M | — | -7.16 | −$91.9M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$60.8M | −$59.5M | — | -3.81 | −$27.8M | $182.1M | −$209.9M | — | — |
Every number comes from RELMADA THERAPEUTICS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.